*GENMAB TO ACQUIRE MERUS, EXPANDING LATE-STAGE PIPELINE AND ACCELERATING INTO A WHOLLY OWNED MODEL
*GENMAB A/S - TO BUY MERUS FOR USD 8.0 BILLION
*GENMAB A/S - DEAL EXPECTED TO BE ACCRETIVE TO EBITDA BY 2029
*GENMAB A/S - USD 97.00 PER SHARE REPRESENTS 41% PREMIUM OVER CLOSING PRICE
((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 29-SEP-202505:08:29.18 GMT